Sigilon Therapeutics, Inc. (NasdaqGM: SGTX)
Health Care · Biotechnology · US
$—
— today · — 1Y
Sigilon Therapeutics, Inc. (NasdaqGM: SGTX) operates in the Biotechnology industry within the Health Care sector.
Tweenvest scores Sigilon Therapeutics, Inc. across four factors: quality 35/100, value 63/100. Its strongest factor is value.
SGTX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- —
- Revenue (TTM)
- $17.65M
- P/E
- —
- EPS
- -12.11
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $—
- 52-week low
- $—
- Avg volume (3M)
- —
- Shares outstanding
- —
- Employees
- 62
- Next earnings
- —
About Sigilon Therapeutics, Inc.
Cambridge, Massachusetts-based Sigilon Therapeutics, Inc., established in 2015, functions as a clinical-stage biotechnology firm dedicated to creating lasting solutions for patients grappling with chronic health conditions. Its primary investigational therapy, SIG-001, is currently undergoing Phase I/II clinical assessment to prevent bleeding episodes in individuals suffering from moderate to severe Hemophilia A. The company's research pipeline also encompasses SIG-005, designed to address the non-neurological symptoms associated with mucopolysaccharidosis type 1; SIG-007, engineered to ensure a continuous and sustained delivery of functional enzymes sufficient to generate clinical improvements and halt the advancement of Fabry disease; and SIG-002, an initiative focused on replacing islet cells for the treatment of Type 1 Diabetes. Furthermore, Sigilon Therapeutics holds a collaborative research and licensing agreement with Eli Lilly and Company for the advancement and market release of SLTx product candidates targeting Type 1 Diabetes. Originally known as Sigilon, Inc., the company officially adopted its current name in June 2017.
- ISIN
- US82657L2060
- Founded
- 2015
- Listed since
- Dec 4, 2020
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| PhaseRx, Inc.OTCPK: PZRX.Q | $12.00 | $— | — |
| ContraFect CorporationOTCPK: CFRX.Q | $11.00 | $0.00 | — |
| Notable Labs, Ltd.OTCPK: NTBL.Q | $10.00 | $— | — |
| OncoSec Medical IncorporatedOTCPK: ONCS.Q | $6.00 | $0.00 | — |
| Calithera Biosciences, Inc.OTCPK: CALA | $5.00 | $0.00 | -99.00% |
| Biocept, Inc.OTCPK: BIOC.Q | $3.00 | $0.00 | -99.50% |
| Yield10 Bioscience, Inc.OTCPK: YTEN.Q | $1.00 | $— | — |
| LadRx CorporationOTCPK: LADX | $0.00 | $0.00 | -99.50% |
Figures last refreshed Oct 18, 2026.